M&A | pharmaphorum

Wednesday 23 September 2026

M&A

News

Merck fires up a $10.8bn Prometheus takeover bid

Merck fires up a $10.8bn Prometheus takeover bid

Merck & Co has reached an agreement to buy Prometheus Biosciences in a $200-per-share cash transaction that values the San Diego-based biotech at $10.8 billion.

News

Pressure raises on Illumina as FTC orders it to shed Grail

Pressure raises on Illumina as FTC orders it to shed Grail

The Federal Trade Commission has ordered Illumina to divest Grail, the cancer detection business it bought for $7.1 billion in 2021, saying it will “stifle” competition an

News

Jounce Therapeutics

Jounce elopes with Concentra, leaving Redx at the altar

A $425 million proposed marriage between Redx Pharma of the UK and Jounce Ther

News

Illumina says Icahn’s board candidates “do not add value”

Illumina says Icahn’s board candidates “do not add value”

Icahn's board picks "will damage Illumina’s core business," says the gene sequencing company.

News

merger three way

Concentra gatecrashes Jounce and Redx’ merger party

Biotech interloper is led by Kevin Tang of Tang Capital management, which owns 10% of Jounce.

News

Rumour of Pfizer, Seagen deal is true, with $43bn price tag

Rumour of Pfizer, Seagen deal is true, with $43bn price tag

Pfizer says Seagen's current and future drugs could add $10 billion to its revenues from 2030.